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Congenital disorders of glycosylation (CDG) are inherited autosomal-recessive diseases that impair N-glycosylation. Approximately 20%
of patients do not survive beyond the age of 5 years old as a result of widespread organ dysfunction. Although most patients receive
a CDG diagnosis based on abnormal glycosylation of transferrin, this test cannot provide a genetic diagnosis; indeed, many patients
with abnormal transferrin do not havemutations in any knownCDGgenes. Here, we combined biochemical analysis withwhole-exome
sequencing (WES) to identify the genetic defect in an untyped CDG patient, and we found a 22 bp deletion and a missense mutation in
DDOST, whose product is a component of the oligosaccharyltransferase complex that transfers the glycan chain from a lipid carrier to
nascent proteins in the endoplasmic reticulum lumen. Biochemical analysis with three biomarkers revealed that N-glycosylation was
decreased in the patient’s fibroblasts. Complementation with wild-type-DDOST cDNA in patient fibroblasts restored glycosylation,
indicating that the mutations were pathological. Our results highlight the power of combiningWES and biochemical studies, including
a glyco-complementation system, for identifying and confirming the defective gene in an untyped CDG patient. This approach will be
very useful for uncovering other types of CDG as well.Glycosylation is the biosynthetic process of adding glycans
to proteins and lipids and is an important modification of
secretory andmembrane-bound proteins. About 1%–2% of
the genome is believed to be involved in glycosylation.1
Defects within the N-glycosylation biosynthesis pathway
that alter the assembly or processing of glycans result in
congenital disorders of glycosylation (CDG).2,3 Symptoms
of CDG often begin in infancy, and nearly all organs,
particularly the nervous system, can be affected.4,5 The
80% of patients who survive the first 5 years often have
medical problems for the rest of their lives.6,7 The spectrum
and severity of organ dysfunction is very broad, making
the clinical diagnosis of this group of disorders especially
challenging. There is currently an effective treatment
for only one CDG subtype, namely, MPI-CDG (CDG-Ib
[MIM 602579]), via oral mannose supplementation.2
Although some types of CDG can be diagnosed via a blood
test for the glycosylation status of serum transferrin, lipid-
linked oligosaccharide analysis in fibroblasts, enzymatic
tests, and mutation analysis, such strategies leave a signifi-
cant number of CDG patients without a molecular diag-
nosis. Here, we have combined whole-exome sequencing
(WES) with biochemical and functional analysis to identify
the defective gene in an untyped CDG patient.
Clinical data, serum, and DNA samples were collected
under research projects approved by the institutional
review board of the Sanford-Burnham Medical Research
Institute, and informed consent was obtained from the
patient’s family. At 6 months of age, the patient (CDG-
0235), a male of northern European descent born in
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The Americareflux disease, developmental delay, ear infections, and
oromotor dysfunction; hypotonia, external strabismus,
and mild to moderate liver dysfunction were noted at
1 year of age. The patient did not walk until 3 years
of age. At 5 years old, his fine motor skills were at the
26 month level, and his gross motor skills were at the
16 month level. He experienced frequent constipation
and a deficiency of factor XI, antithrombin-III, protein C,
and protein S at 6 years of age. Brain magnetic resonance
imaging suggested disordered myelination. The patient
also had slightly advanced bone age and mild osteopenia.
When he was 7 years old, he had two episodes of tremors
that affected the extremities and that were not clearly asso-
ciated with loss of consciousness. Upon his last evaluation
at 7.5 years of age, his weight, height, and head circumfer-
ence were in the 52nd, 35th, and below the 50th percentiles,
respectively. He is currently without language and
functions best in a social setting. We analyzed his serum
transferrin by using ESI-MS (electrospray ionization mass
spectrometry) and MALDI-TOF (matrix-assisted laser
desorption/ionization–time of flight), revealing a type 1
pattern in which both monoglycosylated and aglycosy-
lated transferrin were markedly elevated. MALDI-TOF
analysis of both N-linked and O-linked glycans from
whole-serum proteins showed normal glycan structures.
Common secondary glycosylation defects were also
excluded.
Targeted next-generation sequencing analysis of 25
genes associated with CDG failed to uncover any muta-
tions.8 To identify the defective gene in this patient, we
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the Roche NimbleGen SeqCap EZ whole-exome kit
(NimbleGen, Madison WI) and the Illumina HiSeq plat-
form to generate single-end 50 bp reads (San Diego, CA).
NextGENe software mapped the reads to the hg19 refer-
ence genome. Reads were aligned and filtered as described
previously.8 We obtained 7.71 Gb of mappable sequence
data for this patient. Out of a total of 80,048,259 bases,
79,012,293 bases were covered, and there was an average
coverage of 253. More than 84% of the targeted regions
had greater than 103 coverage. From an internally gener-
ated list of ~250 genes involved in glycosylation, a total
of 311 variants were detected in the coding regions and
dinucleotide splice sites of these genes, and 213 of those
were nonsynonymous. A total of 92 variants were detected
in the noncoding regions up to þ20 or 20 bases into the
intron.
WES detected two mutations in DDOST (MIM 602202),
which encodes a 48 kDa subunit of the N-glycosylation
oligosaccharyltransferase (OST) complex (RefSeq acces-
sion number NM_005216.4). Using Sanger sequencing,
we detected one copy of a 22 bp deletion in exon 11
(c.1265_1286del22) and one copy of a missense mutation
(c.650G>A) that was predicted to change glycine to
aspartic acid at codon 217 (p.Gly217Asp) in exon 6 (Fig-
ure 1). This particular glycine residue is highly conserved,
and PolyPhen, SIFT, and PANTHER all predicted the
mutation to be damaging.9 The deletion, on the other
hand, creates a stop codon 7 amino acids downstream
(p.Ile422Thrfs*7) and truncates 29 C-terminal amino acids.
The mutant-allele percentages of the deletion and mis-
sense mutation were 41% and 64%, respectively, and their
respective coverages were 443 and 363. Neither mutation
was present in the 1000 Genomes Project, in the dbSNP
database, or in 100 ethnically matched controls (data not
shown). Family studies confirmed that the missense muta-
tion was inherited from the mother and that the deletion
was inherited from the father (Figure 1).
The missense mutation detected in exon 6 of DDOST is
present in the luminal domain of the endoplasmic retic-
ulum (ER) and substitutes a highly conserved hydrophobic
amino acid with a negatively charged hydrophilic amino
acid that most likely impairs DDOST function. The dele-
tion in exon 11 is adjacent to the transmembrane domain
in the lumen of the ER and includes a small portion of
the transmembrane domain. This deletion produces a
protein with a 29 amino acid C-terminal truncation, which
is presumably nonfunctional. We hypothesized that the
mutations detected in patient CDG-0235 would impair
DDOST function, most likely resulting in protein hypogly-
cosylation.
We then investigated whether these mutations impaired
glycosylation in the patient. Using a polyclonal DDOST
antibody (D6820 Sigma), we performed immunoblot
analysis on patient fibroblasts and found that there was
a ~50% reduction in protein expression (Figure S1, avail-
able online). We saw no smaller bands, suggesting that
the truncated protein was probably unstable and degraded.364 The American Journal of Human Genetics 90, 363–368, FebruaryWe used three markers to assess the glycosylation status of
patient fibroblasts. One marker is an engineered DNase-I
with a single glycosylation site that is required for normal
secretion into the media when expressed in human
fibroblasts.10,11 DNase-I experiments were performed as
described elsewhere.12 Secreted DNase-I in fibroblasts of
the patient and other CDG patients was strongly reduced
compared to that in control fibroblasts (Figure 2A).13,14
ICAM-1 is another marker that normally localizes in the
plasma membrane, but it is degraded and rendered un-
stable by hypoglycosylation. We analyzed ICAM-1 expres-
sion in the patient fibroblasts by using flow cytometry with
fluorescein isothiocyanate (FITC) anti-human ICAM-1
antibody (BioLegend, San Diego, CA). We also used immu-
nofluorescence (IF) of ICAM-1 and immunoblot analysis
with a monoclonal ICAM-1 antibody (R&D Systems,
Minneapolis, MN) to assess ICAM-1 levels in patient
fibroblasts. Previously, ICAM-1 expression in membrane
fractions from CDG patients’ fibroblasts was found to be
absent or significantly reduced (He and Freeze, unpub-
lished results; He et al. in preparation). ICAM-1 was also
absent from the membranes of patient fibroblasts
(Figure 2B–2D).
A third marker is an engineered green fluorescent
protein (GFP) containing ER-targeting and ER-retention
signals along with an N-glycosylation site (Glyc-ER-GFP).
When the glycosylation site is occupied, fluorescence is
lost as a result of steric hindrance by the N-glycan.
However, fluorescence appears normal when the site is
unoccupied. GFP fluoresces in fibroblasts from patients
with several different CDG types, indicating a glycosyla-
tion defect (Losfeld et al. in preparation). We transfected
two control fibroblast cell lines, 12F and 50F, and patient
fibroblasts with ER-GFP, which is an ER-retained construct
without the engineered glycosylation site as a control, and
Glyc-ER-GFP to assess glycosylation status. We also incu-
bated control fibroblasts with tunicamycin 24 hr after
transfection to inhibit N-glycosylation. Control fibroblasts
containing Glyc-ER-GFP lacked fluorescence (Figure 3A)
because the N-glycosylation site was occupied, but nongly-
cosylated ER-GFP fluoresced. However, the fibroblasts
transfected by Glyc-ER-GFP and treated with tunicamycin
produced a fluorescence pattern indicating hypoglycosyla-
tion in these cells. In parallel, patient cells transfected
by Glyc-ER-GFP showed a bright fluorescence without
treatment, demonstrating an N-glycosylation deficiency
(Figure 3A).
To confirm whether the DDOST mutations caused
protein hypoglycosylation in vitro, we complemented
cells with normal DDOST cDNA. This cDNA was cloned
from a testis cDNA library and engineered to have an in-
frame C-terminal dsRED fusion. The resulting dsRED-
DDOST was then cloned into pBABE-Puro vector. 293T
cells were transfected with 10 mg of pCL-Ampho (Imgenex
Corp, San Diego CA) and 10 mg of pBABE-puro, dsRED-
DDOST, or an empty vector. Viral supernatant was
collected, patient fibroblasts were infected, and stable cell10, 2012
Figure 1. NGS Detection, Sanger-Sequencing Confirmation of Mutations in DDOST, and Pedigree for Patient CDG-0235
(A) NGS detection (labeled by arrow) of c.650G>A in exon 6.
(B) NGS detection (labeled by arrow) of c.1265_1286 del22 in exon 11.
(C) Sanger-sequencing confirmation of c.650G>A (labeled by arrow).
(D) Sanger-sequencing confirmation of c.1265_1286 del22 (labeled by arrow).
(E) Family pedigree showing that patient CDG-0235 inherited the missense mutation from his mother and the 22 bp deletion from his
father. One sibling inherited the missense mutation, and the other sibling did not inherit either mutation.lines were created. Using the Glyc-ER-GFP marker, we
established patient cell lines by stably expressing either
the mock vector or the wild-type DDOST. The comple-
mented cell lines were then transfected with ER-GFP and
Glyc-ER-GFP, and the relative fluorescence was monitored.
Maximum fluorescence decreased by ~18% in the patient
cells overexpressing wild-type DDOST compared to that
in the control cells (Figure 3B) (Image J software). Addition-The Americaally, we evaluated ICAM-1 expression. Patient fibroblasts
with wild-type DDOST had increased ICAM-1 mem-
brane expression compared to patient fibroblasts contain-
ing the empty vector (Figure 4A). Immunoblot analysis
showed that ICAM-1 expression in patient fibroblasts in-
fected with viruses expressing the wild-type-DDOST
cDNAwas more than three times greater than that of fibro-
blasts infected with the empty vector (Figure 4B). Thesen Journal of Human Genetics 90, 363–368, February 10, 2012 365
Figure 2. Glycosylated Expression of
DNase-I and ICAM-1 in Patient CDG-
0235 is Reduced, Indicating a Glycosyla-
tion Defect
(A) DNase-I expression: the top band repre-
sents glycosylatedDNase-I, and thebottom
band represents nonglycosylated DNase-I.
Expression of glycosylated DNase-I in
patient CDG-0235 is reduced compared to
that in both 12F and 50F normal controls.
(B) Flow cytometry detected a lower level
of ICAM-1 expression at the cell surface
in the patient compared to the control.
(C) Immunoblot analysis determined
an absence of ICAM-1 expression in the
patient fibroblasts compared to the con-
trol fibroblasts 50F and 42F and the addi-
tional Type 1a and Type Ib CDG patient
fibroblasts.
(D) IF staining detected an absence of
ICAM-1 expression in patient fibroblasts
compared to control fibroblasts.studies demonstrate that introduction of wild-typeDDOST
restored glycosylation in our patient’s fibroblasts, meaning
that the mutations identified in DDOST are probably
pathogenic.
Here, we report a CDG patient with mutations in
DDOST. This gene is localized in chromosomal region
1p36.1, contains 11 coding exons, and spans 9 kb of
sequence.9 The protein product is a component of the
OST complex and was first characterized in yeast.15 The
OST complex is specific to the N-glycosylation pathway
and is responsible for transferring glycans from lipid-
linked oligosaccharides to proteins.16,17 The mammalian
OST complex consists of seven subunits: RPN1, RPN2,366 The American Journal of Human Genetics 90, 363–368, FebruaryDDOST, DAD1, STT3A or STT3B, TUSC3 or MAGT1,
and OST4.18
The function of DDOST has yet to be fully elucidated.
Yeast strains deficient in DDOST have reduced OST activity
and a destabilized OST complex,15,19 and impaired DDOST
leads to underglycosylation of glycoproteins.15 DDOST
is believed to recognize the dolichol-P-P-oligosaccharide
and provide the oligosaccharide donor and acceptor
binding sites that are critical for enzyme activity.20,21
Four patients with nonsyndromic intellectual disability
have been identified with mutations in the OST subunits
TUSC3 (MIM 601385) and MAGT1 (MIM 300715).22 Inter-
estingly, these patients did not show hypoglycosylation ofFigure 3. GFP Expression in Patient CDG-0235
Indicates a Glycosylation Deficiency
(A) ER-GFP is not glycosylated and fluoresces in
controls 12F and 50F and in patient CDG-0235.
Controls 12F and 50F transfected by Glyc-ER-
GFP and treated with the glycosylation inhibitor
tunicamycin show bright fluorescence, indi-
cating reduced glycosylation. Patient CDG-0235
cells transfected by Glyc-ER-GFP had bright fluo-
rescence without treatment of tunicamycin com-
pared to the controls cells, indicating a reticular
N-glycosylation deficiency consistent with a
CDG-type-I defect.
(B) CDG-0235 cells were complemented with
either the mock vector or the wild-type DDOST.
Complementation with wild-type DDOST in
patient cells reduced the amount of GFP expres-
sion compared to patient cells complemented
with the mock vector, indicating that the intro-
duction of wild-type DDOST in patient cells
restores glycosylation. The error bars represent
standard deviations based on an average of 5
images from each group.
10, 2012
Figure 4. Complementation of Patient CDG-
0235 Cells with Wild-Type DDOST Restores
Cell-Surface ICAM-1 Expression
(A) Patient fibroblasts complemented with wild-
type-DDOST cDNA tagged with dsRed were gated
into OST-positive and OST-negative groups ac-
cording to red-fluorescence intensity. Patient
cells complemented with wild-type DDOST
(CDG235þDDOST) had significantly increased
ICAM-1 expression compared to patient cells
with the empty vector (CDG235).
(B) Immunoblot analysis revealed that ICAM-1
expression in patient cells complemented with
wild-type-DDOST cDNA (235þDDOST) was
more than three times greater than that of
empty-vector (235þv)-transduced patient fibro-
blasts.transferrin, suggesting that either brain-specific glycopro-
teins are affected or the impact on transferrin was unde-
tectable.22 In 50 other untyped CDG patients, we found
no variants that were predicted to impairDDOST function.
Given that mutations within the OST complex result in
a fairly mild phenotype and can result in intellectual
disability, this gene might be of interest in patients with
intellectual disability.
Our WES-analysis pipeline first focuses on a library of
250 glycosylation genes. Analysis of the types of variants
detected in the glycan-gene library and whether they are
present in dbSNP or the 1000 Genomes Project can aid in
the selection of candidate variants for Sanger-sequencing
confirmation. The 22 bp deletion detected inDDOST along
with the missense mutation led us to focus on this gene.
Candidates identified with WES must be confirmed by
functional biochemical tests or by surrogate markers for
a glycosylation deficiency in patient cells. In this study,
we used our recently developed glycosylation makers to
show that complementing patient fibroblasts with wild-
type-DDOST cDNA substantially restored glycosylation.
These markers, ICAM-1 and Glyc-ER-GFP, can be used in
general for the assessment of complementation in cells
that lack full glycosylation site occupancy, regardless of
the putative gene defect identified by WES.
More patients will probably be found with defects in
the other OST subunits. It will be interesting to see
whether these patients can be detected by the transferrin
screening test, given that this test produced normal
results for the previously reported OST-subunit defects
(TUSC3-CDG and MAGT1-CDG).22 Finally, patients with
OST-subunit defects can give us insight into the impor-
tance of each subunit to OST function on the basis of
their associated phenotypes. In accordance with the
recently introduced CDG nomenclature, we label this
disease DDOST-CDG.23Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cell.com/AJHG.The AmericaAcknowledgments
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